Dr Georgia Papathomas joins Indegene’s Board as Independent Director

Papathomas brings several years of experience in life sciences

Indegene, a digital-first, life sciences commercialization company, announced the appointment of Georgia Papathomas as a Non-Executive Independent Director to the Board.

Papathomas brings several years of experience in life sciences. She works closely with many innovative healthcare and technology companies as an advisor and board member. Papathomas worked at Johnson & Johnson in her last corporate role.

“Life sciences companies are increasingly looking to personalize the patient and physician experience through omnichannel journeys. They are aiming to transform operations across the commercialization value chain with a digital-first approach,” said Manish Gupta, CEO, Indegene.

“I am excited to welcome Georgia to our Board at this interesting time in the industry. Her experience in building and managing teams at various life sciences companies, coupled with her engagement with new-age health-tech startups, will help us greatly as we prepare for Indegene’s next phase of growth.”

“Indegene is helping global life sciences organisations in an increasingly complex business environment. The company is propelled by an experienced leadership team, with a deep understanding of the sector and a focus on execution at scale,” said Papathomas. “I am excited to join Indegene’s Board in their growth journey and I look forward to supporting the company’s future endeavours using my experience in leading innovative, diverse global teams around the world.”

Papathomas is an executive advisory board member of numerous organisations, including the Executive Board of the National Center for Women & Information Technology, the Board of Advisor of Homeless Solutions, and Columbia University School of Engineering and Applied Science (also known as Fu Foundation School of Engineering and Applied Science).


Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.


Related Articles

Back to top button